 This is a pilot, randomized, open-labelled study. Eligible patients will be enrolled and randomized 1:1 into anticoagulation arm or anticoagulation plus atorvastatin arm, with atorvastatin given at 40 mg orally daily for 3 months. The targeted total accrual is 80 patients, with 40 in each arm. Patients will be recruited from the hospitals and clinics at The Ohio State University Wexner Medical Center. Follow up visits are planned at enrollment, 3 months, and 9 months after randomization. At each follow up, blood will be obtained and assessments will include structured interviews of signs and symptoms of recurrent venous thromboembolism VTE, bleeding, post thrombotic syndrome, and adverse events from study drugs. 